Navigation Links
Eli Lilly India and Lupin Announce Strategic Collaboration to Help Fight the Battle Against Diabetes
Date:7/29/2011

ficant presence in Cardiovasculars, Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs in addition to holding global leadership positions in the Anti-TB and Cephalosporins space.

Today, Lupin is the 5th largest and the fastest growing generics player in the U.S. (by prescriptions), the only Asian company to achieve that distinction. The company is also the fastest growing top 10 pharmaceutical players in India, Japan and South Africa. (IMS Health)

For the financial year ended March 2011, Lupin's Consolidated Sales and Profit after Tax were Rs. 57,068 million (USD 1.28 Billion) and Rs. 8,626 million (USD 193 million) respectively.  Please visit http://www.lupinworld.com  for more information.

This press release contains forward-looking statements about a strategic collaboration to market insulin products.  It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. There is no guarantee that these products will continue to be commercially successful or that the collaboration will produce expected results. For further discussion of these and other risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

C-LLY

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... and HERZLIYA PITUACH, Israel, Nov. 25, 2014 ... or "the Company"), a clinical stage biopharmaceutical company ... targeted therapeutics for the treatment of inflammatory diseases ... previously announced underwritten public offering of 3,450,000 units, ... the Company,s common stock, par value $0.0001 per ...
(Date:11/24/2014)... -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today that ... update at the Piper Jaffray 26 th Annual Healthcare ... Time (5:30 a.m. Pacific Time), at The New York Palace ... A live audio webcast of the presentation will be available ... www.arenapharm.com . A replay of the presentation will be available ...
(Date:11/24/2014)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing ... today that Sergio Traversa , chief executive officer, ... Event" Micro-Cap Growth Conference on Wednesday, December 3, 2014.  ... Bel Air Hotel, which is located at 11461 Sunset ... The presentation is scheduled for 8:30 a.m. ...
Breaking Medicine Technology:Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 3Relmada Therapeutics To Present At LD MICRO Conference 2
... , MISSISSAUGA, Ontario, Dec. 30 ... Holdings Inc. (OTC Bulletin Board: CGNH), a developer of ... IVD testing market, was interviewed in MedTech Executive. ... for developing its QL Care Analyzer device, the FDA ...
... , BOSTON, Dec. 30 Solos Endoscopy, ... looks forward to a prosperous 2010, following a solid year in ... , In the closing months of 2009, Solos Endoscopy, Inc. has ... MammoView(TM) line of surgical endoscopy instruments. This will allow the MammoView(TM) ...
Cached Medicine Technology:Dr. Yahia Gawad, CEO of CardioGenics Holdings, Inc., Interviewed in MedTech Executive 2Dr. Yahia Gawad, CEO of CardioGenics Holdings, Inc., Interviewed in MedTech Executive 3Dr. Yahia Gawad, CEO of CardioGenics Holdings, Inc., Interviewed in MedTech Executive 4Solos Endoscopy, Inc. Set to Increase Business Through Sales and Product Development in 2010 2
(Date:11/26/2014)... the video interviewing specialist, has today announced the appointment ... Officer, in addition to the formal opening of it’s ... appointed as Chief Operating Officer. He is joined by ... Officer. , Mr Jones is a seasoned tech, media ... with The Walt Disney Company and Adventis where he ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Anthropologists ... effectiveness in containing and stopping Ebola, improve international ... in healthcare systems in West Africa. , ... to Stop Ebola: Anthropologists Offer Insights,” will be ... the American Anthropological Association (AAA), Fri., Dec. 5, ...
(Date:11/26/2014)... Medical suction and vacuum products have a ... score represents steady growth in the price of medical ... a result of swelling demand for healthcare services and ... considered nondiscretionary. IBISWorld market research analyst, Anna Son, says, ... of flexibility, given the low level of price volatility ...
(Date:11/26/2014)... For those with a New Year’s resolution to ... classes at the University of Colorado Anschutz Health and ... for. The 45- 60 minute classes have just started and ... fitness club memberships. , LES MILLS BODYPUMP™ exercise classes strengthen, ... aimed at fast results , By focusing on low ...
(Date:11/26/2014)... November 26, 2014 News Facts ... expanded capabilities at RSNA 2014 in Chicago. The ... and share diagnostic images, photos, videos and documents ... booth #8107 will learn more about these innovative ... technologies and partner initiatives – that enable more ...
Breaking Medicine News(10 mins):Health News:Sonru Expansion continues with appointment of new executive team and opening of new London base 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 3Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Medical Suction & Vacuum Products Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 3
... to Accelerate Adoption, WASHINGTON, Dec. 5 ... improve health care through electronic prescribing (e-prescribing), ... bipartisan,legislation introduced by Senate Finance Committee Members ... (D-Mich.), Senator Mel,Martinez (R-Fla.), and endorsed by ...
... Two studies support efforts to reduce air pollution, especially ... Two real-world studies from Europe demonstrate the health damage ... by diesel engines. , An 11-year period of improving ... the cleanest air in Europe, produced measurable benefits in ...
... portfolio, SHAWNEE, Kan., Dec. 5 AVP ... industry, will change its name to Avascend,effective December ... brand is the,expanded service portfolio and the same ... Avascend currently provides the following core healthcare hospitality,services: ...
... lifestyle drives new store openings, PITTSBURGH, Dec. 5 ... resolution or two. For GNC, it means more new ... expected to rise steadily,through 2012, according to the Nutrition ... once again expand its store base and overall,business: The ...
... DND, MISSISSAUGA, ON, Dec. 5 /PRNewswire-FirstCall/ - ... Stefan Aigner, M.D., CFA, has been,appointed to its ... than 20 years of experience in the global,healthcare ... Business,Development for Alpharma, Inc. (NYSE: ALO ), ...
... Ventas, Inc. (NYSE:,VTR) ("Ventas" or the ... of its Board of Directors has granted ... to encourage their,long-term retention and reward performance. ... the Company,s Chief Investment Officer, Richard A.,Schweinhart, ...
Cached Medicine News:Health News:PCMA Supports Bipartisan Legislation Calling for E-Prescribing Requirement in Medicare 2Health News:Cleaner Air Leads to Healthier Lungs 2Health News:Cleaner Air Leads to Healthier Lungs 3Health News:AVP is Now Avascend 2Health News:GNC Franchising Expected to Grow Through 2008 2Health News:Cipher appoints Stefan Aigner to board of directors 2Health News:Cipher appoints Stefan Aigner to board of directors 3Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 2Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 3Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 4
The Fathom Guidewire combines a nitinol hypotube distal segment with advanced microfabrication technology, creating a design that revolutionizes access of the most tortuous vasculature....
... for stent delivery. Uses perpendicular applied ... Allows user to adjust stent position ... tactile feel via fine adjustment and ... visualization at any angle. The Cordis ...
Vial with 100 Urine Reagent Test Strips, tests for glucose, protein, pH, blood, ketone, bilirubin, nitrite, urobilinogen, specific gravity. FOR LABORATORY USE BY QUALIFIED TECHNICIANS....
... the latest from Quality Mapping Solutions, ... designed specifically for implementing and managing ... superior design, functionality, security, and versatility ... managing a quality program., ,Based upon ...
Medicine Products: